These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23053402)

  • 1. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
    Ogawa T; Niho S; Nagai S; Kojima T; Nishimura Y; Ohe Y; Kondo N; Yamaguchi T; Endo K; Izumi K; Minami H
    Int J Clin Oncol; 2013 Dec; 18(6):977-82. PubMed ID: 23053402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
    Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
    Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
    Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
    Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
    Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
    Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
    Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
    Takagi M; Sagara A; Ishizawa A; Ito A; Miyazaki M; Senzaki K; Nagai T; Yamada K
    Yakugaku Zasshi; 2019; 139(10):1327-1332. PubMed ID: 31582618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
    Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
    J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
    Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin Induced Renal Insufficiency Measured by Glomerular Filtration Rate with
    Khurana R; Deswal S; Prakash C; Singh DK
    J Clin Diagn Res; 2016 Dec; 10(12):XC05-XC07. PubMed ID: 28208988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
    Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
    Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal tolerance of cisplatin in patients more than 80 years old.
    Thyss A; Saudes L; Otto J; Creisson A; Gaspard MH; Dassonville O; Schneider M
    J Clin Oncol; 1994 Oct; 12(10):2121-5. PubMed ID: 7931482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
    Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
    Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity.
    Koçak G; Bilik G; Yeşilova A; Oyman F; Can M; Cihan Ş
    Medicine (Baltimore); 2022 Jul; 101(26):e29814. PubMed ID: 35777022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. eGFR is a reliable preoperative renal function parameter in patients with gastric cancer.
    Kosuge T; Sawada T; Iwasaki Y; Kita J; Shimoda M; Tagaya N; Kubota K
    World J Gastroenterol; 2010 May; 16(19):2417-20. PubMed ID: 20480529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cisplatin in patients with advanced malignancies.
    Blumenreich MS; Woodcock TM; Jones M; Richman SP; Gentile PS; Kubota TT; Allegra JC
    Cancer; 1985 Mar; 55(5):1118-22. PubMed ID: 4038468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
    Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
    Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.